This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Tremfya (guselkumab)
General Description:
Tremfya (guselkumab) is a fully human monoclonal antibody used for the treatment of adult patients with moderate-to-severe plaque psoriasis and active psoriatic arthritis.
It works by selectively targeting and blocking interleukin-23 (IL-23), a key cytokine involved in the inflammatory processes that drive psoriasis and psoriatic arthritis. By inhibiting IL-23, Tremfya helps reduce skin inflammation, scaling, and joint pain, leading to clearer skin and improved physical function in patients.
Disease Indications:
• Plaque Psoriasis
• Psoriatic Arthritis (PsA)
Manufacturer:
Janssen Biotech
Usage:
Subcutaneous Injection
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
• Health Canada
• Pharmaceuticals and Medical Devices Agency (PMDA)
• Therapeutic Goods Administration (TGA)
Package:
• Single-dose pre-filled syringe: 100 mg/mL guselkumab
Shipping:
Cold Chain Shipping
Tremfya contains temperature-sensitive biological ingredients that require protection from heat, light, and improper handling. To ensure the medicine remains stable and effective, it is shipped under cold chain delivery conditions using specialized medical couriers with temperature-controlled vehicles and packaging.
While cold chain shipping can be more expensive than standard delivery, it guarantees that Tremfya arrives in optimal condition for safe and effective use by patients.
How to Access Tremfya (guselkumab) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Tremfya (guselkumab) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in obtaining it legally through the Named Patient Program (NPP).
Here’s how the process works:
